Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 596.00 GBp
Change Today -3.00 / -0.50%
Volume 471.2K
GWP On Other Exchanges
Symbol
Exchange
OTC US
NASDAQ GM
NASDAQ GM
Stuttgart
As of 11:35 AM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

gw pharmaceuticals plc (GWP) Snapshot

Open
575.00 GBp
Previous Close
599.00 GBp
Day High
600.00 GBp
Day Low
570.00 GBp
52 Week High
04/27/15 - 697.00 GBp
52 Week Low
10/16/14 - 299.50 GBp
Market Cap
1.5B
Average Volume 10 Days
614.4K
EPS TTM
-0.07 GBp
Shares Outstanding
256.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GW PHARMACEUTICALS PLC (GWP)

gw pharmaceuticals plc (GWP) Details

GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates in three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of multiple sclerosis symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.

294 Employees
Last Reported Date: 02/4/15
Founded in 1998

gw pharmaceuticals plc (GWP) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: 567.8K GBP
Founder, Executive Chairman and Chairman of N...
Total Annual Compensation: 696.1K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 389.8K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 421.8K GBP
Research & Development Director and Executive...
Total Annual Compensation: 475.3K GBP
Compensation as of Fiscal Year 2014.

gw pharmaceuticals plc (GWP) Key Developments

GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy

GW Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Cannabidiol (CBD) for use in treating newborn children with neonatal hypoxic-ischemic encephalopathy (NHIE). NHIE is acute or sub-acute brain injury due to asphyxia caused during the birth process and resulting from deprivation of oxygen during birth (hypoxia). The incidence of NHIE is 1.5 to 2.8 per 1,000 births in the United States, or, 6,500 to 12,000 cases per year. Of these, 35% are expected to die in early life and 30% may suffer from permanent disability. There are currently no FDA-approved medicines specifically indicated for NHIE. GW has developed an intravenous CBD formulation for use in this patient population. GW held a pre-IND meeting with the FDA and expects to submit an Investigational New Drug Application (IND) in mid-2015 and to commence a Phase 1 trial in the second half of 2015. GW has been conducting pre-clinical research into the neuroprotective effects of CBD in animal models of NHIE since 2008. Publications from this research have shown that CBD reduces neurologic disability across a range of newborn animal models of brain hypoxia.

GW Pharmaceuticals plc Announces New Physician Reports of Epidiolex Treatment

GW Pharmaceuticals plc announced new physician reports of clinical effect and safety associated with the Epidiolex expanded access program. These data were presented by study authors at the American Academy of Neurology annual meeting in Washington DC1. Physician reports of clinical effect and safety data have been presented on 137 children and young adults with treatment-resistant epilepsy who have been treated with GW's investigational cannabidiol (CBD) product candidate, Epidiolex, for a period of at least 12 weeks. These data are from eleven hospital sites in the United States and were generated under expanded access Investigational New Drug applications (INDs) authorized by the U.S. Food and Drug Administration (FDA). In addition, physician reports of safety data were presented on 213 patients (137 patients with twelve weeks treatment effect data plus additional patients still in their first twelve weeks of treatment or who withdrew from treatment). The expanded access program is comprised of clinical studies performed by individual physicians. FDA authorized expanded access programs facilitate access to investigational drugs for treatment use for patients with a serious or immediately life-threatening diseases or conditions who lack therapeutic alternatives. The patients included in the Epidiolex program had Dravet syndrome (18% of the total) and Lennox-Gastaut syndrome (LGS) (16% of the total), epilepsy types that can lead to intellectual disability and lifelong seizures, as well as 10 other types of severe epilepsy. Many of the 10 other types of epilepsy are extreme and rare, and several patients with these epilepsies have major congenital structural brain abnormalities. The 137 patients were predominately children with an average age of 11 years. In all cases, Epidiolex was added to current anti-epileptic drug (AED) treatment regimes. On average, patients were taking approximately 3 other AEDs.

GW Pharmaceuticals plc - Special Call

To discuss the New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GWP:LN 596.00 GBp -3.00

GWP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cannabis Science Inc $0.03 USD -0.0005
Medical Marijuana Inc $0.08 USD -0.0008
PharmaCyte Biotech Inc $0.15 USD -0.0026
View Industry Companies
 

Industry Analysis

GWP

Industry Average

Valuation GWP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 44.9x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 44.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GW PHARMACEUTICALS PLC, please visit www.gwpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.